APA (7th ed.) Citation

Yoo, K. H., Yoon, S. E., Kang, K., Yi, J. H., Kim, M. K., Kim, H. J., . . . Kim, K. (2026). A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906). Cancer Research & Treatment, 58(3), 963. https://doi.org/10.4143/crt.2025.426

Chicago Style (17th ed.) Citation

Yoo, Kwai Han, et al. "A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)." Cancer Research & Treatment 58, no. 3 (2026): 963. https://doi.org/10.4143/crt.2025.426.

MLA (9th ed.) Citation

Yoo, Kwai Han, et al. "A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)." Cancer Research & Treatment, vol. 58, no. 3, 2026, p. 963, https://doi.org/10.4143/crt.2025.426.